Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Over the past decade, the clinical utility of monoclonal antibodies has been realized and
antibodies are now a mainstay for the treatment of cancer. Antibodies have the unique …

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable
success in recent years. Antibody–drug conjugates are powerful new treatment options for …

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that
antibodies possess several clinically relevant mechanisms of action. Many clinically useful …

During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …

Since the advent of hybridoma technology, dating back to 1975, monoclonal antibodies
have become an irreplaceable diagnostic and therapeutic tool for a wide array of human …

A quarter of a century after their advent, monoclonal antibodies have become the most
rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases …

The potential of monoclonal antibodies to effectively treat cancer is beginning to be widely
acknowledged. Advances in antibody engineering make it possible to produce various …

Monoclonal antibody-based treatment of cancer has been established as one of the most
successful therapeutic strategies for both hematologic malignancies and solid tumors in the …

Highlights•Monoclonal antibodies are effective treatment for various cancers and
autoimmune diseases.•Immune checkpoint therapy in cancer has emerged as a potent …